Search Page

1

Cite

Share

Mitochondrial Processes in Targeted Cancer Therapy.

Krejčíř R, Valík D, Vojtěšek B. Krejčíř R, et al. Among authors: valik d. Klin Onkol. 2018 Winter;31(Suppl 2):14-20. doi: 10.14735/amko20182S14. Klin Onkol. 2018. PMID: 31023019 Review. English.

Cite

Share

2

Cite

Share

Host-dependent variables: The missing link to personalized medicine.

Demlova R, Zdrazilova-Dubska L, Sterba J, Stanta G, Valik D. Demlova R, et al. Among authors: valik d. Eur J Surg Oncol. 2018 Sep;44(9):1289-1294. doi: 10.1016/j.ejso.2018.04.014. Epub 2018 Apr 26. Eur J Surg Oncol. 2018. PMID: 29735363 Review.

Cite

Share

3

Cite

Share

N-Glycome changes reflecting resistance to platinum-based chemotherapy in ovarian cancer.

Zahradnikova M, Ihnatova I, Lattova E, Uhrik L, Stuchlikova E, Nenutil R, Valik D, Nalezinska M, Chovanec J, Zdrahal Z, Vojtesek B, Hernychova L, Novotny MV. Zahradnikova M, et al. Among authors: valik d. J Proteomics. 2021 Jan 6;230:103964. doi: 10.1016/j.jprot.2020.103964. Epub 2020 Sep 6. J Proteomics. 2021. PMID: 32898699

Cite

Share

4

Cite

Share

Future paradigms for precision oncology.

Klement GL, Arkun K, Valik D, Roffidal T, Hashemi A, Klement C, Carmassi P, Rietman E, Slaby O, Mazanek P, Mudry P, Kovacs G, Kiss C, Norga K, Konstantinov D, André N, Slavc I, van Den Berg H, Kolenova A, Kren L, Tuma J, Skotakova J, Sterba J. Klement GL, et al. Among authors: valik d. Oncotarget. 2016 Jul 19;7(29):46813-46831. doi: 10.18632/oncotarget.9488. Oncotarget. 2016. PMID: 27223079 Free PMC article. Review.

Cite

Share

5

Cite

Share

Editorial: Precision/Personalized Pediatric Oncology and Immune Therapies: Rather Customize Than Randomize.

Kýr M, Klement GL, Zdrazilova-Dubska L, Demlova R, Valik D, Slaby O, Slavc I, Sterba J. Kýr M, et al. Among authors: valik d. Front Oncol. 2020 Mar 24;10:377. doi: 10.3389/fonc.2020.00377. eCollection 2020. Front Oncol. 2020. PMID: 32269965 Free PMC article. No abstract available.

Cite

Share

6

Cite

Share

BBMRI-ERIC's contributions to research and knowledge exchange on COVID-19.

Holub P, Kozera L, Florindi F, van Enckevort E, Swertz M, Reihs R, Wutte A, Valík D, Mayrhofer MT; BBMRI-ERIC community. Holub P, et al. Among authors: valik d. Eur J Hum Genet. 2020 Jun;28(6):728-731. doi: 10.1038/s41431-020-0634-8. Epub 2020 May 22. Eur J Hum Genet. 2020. PMID: 32444797 Free PMC article.

Cite

Share

7

Cite

Share

Interpretive discrepancies caused by target values inter-batch variations in chemiluminescence immunoassay for SARS-CoV-2 IgM/IgG by MAGLUMI.

Selingerova I, Valik D, Gescheidtova L, Sramek V, Cermakova Z, Zdrazilova-Dubska L. Selingerova I, et al. Among authors: valik d. J Med Virol. 2021 Mar;93(3):1805-1809. doi: 10.1002/jmv.26612. Epub 2020 Nov 1. J Med Virol. 2021. PMID: 33079389

Cite

Share

8

Cite

Share

B-Cell Activating Factor as a Cancer Biomarker and Its Implications in Cancer-Related Cachexia.

Rihacek M, Bienertova-Vasku J, Valik D, Sterba J, Pilatova K, Zdrazilova-Dubska L. Rihacek M, et al. Among authors: valik d. Biomed Res Int. 2015;2015:792187. doi: 10.1155/2015/792187. Epub 2015 Aug 3. Biomed Res Int. 2015. PMID: 26339644 Free PMC article. Review.

Cite

Share

9

Cite

Share

The Clinical Significance of DJ1 and L1CAM Serum Level Monitoring in Patients with Endometrial Cancer.

Bednarikova M, Vinklerova P, Gottwaldova J, Ovesna P, Hausnerova J, Minar L, Felsinger M, Valik D, Cermakova Z, Weinberger V. Bednarikova M, et al. Among authors: valik d. J Clin Med. 2021 Jun 15;10(12):2640. doi: 10.3390/jcm10122640. J Clin Med. 2021. PMID: 34203959 Free PMC article.

Cite

Share

10

Cite

Share

Myeloid-derived suppressor cells (MDSCs) in patients with solid tumors: considerations for granulocyte colony-stimulating factor treatment.

Pilatova K, Bencsikova B, Demlova R, Valik D, Zdrazilova-Dubska L. Pilatova K, et al. Among authors: valik d. Cancer Immunol Immunother. 2018 Dec;67(12):1919-1929. doi: 10.1007/s00262-018-2166-4. Epub 2018 May 10. Cancer Immunol Immunother. 2018. PMID: 29748897 Review.

Cite

Share